Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | HTR3A | P46098 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727924 | 0.82 | HRH3 (0.48) | PDE10AHRH3HTR3AHRH4HTR1A | |
| SCHEMBL1729306 | 0.82 | HRH3 (0.46) | PDE10AHRH3HTR3AHRH4HTR1A | |
| SCHEMBL239841 | 0.80 | HRH3 (0.61) | PDE10AHRH3HTR3AHRH4HTR1A | |
| SCHEMBL1711326 | 0.80 | HTR3A (0.53) | PDE10AHRH3HTR3AHRH4HTR1A | |
| SCHEMBL346050 | 0.80 | HRH3 (0.56) | PDE10AHRH3HTR3AHRH4HTR1A | |
| SCHEMBL2407749 | 0.78 | HRH3 (0.42) | PDE10AHRH3HTR3AHRH4HTR1A | |
| SCHEMBL345053 | 0.78 | HRH3 (0.61) | PDE10AHRH3HTR3AHRH4HTR1A | |
| SCHEMBL1728851 | 0.78 | HRH3 (0.58) | PDE10AHRH3HTR3AHRH4HTR1A | |
| SCHEMBL27829234 | 0.77 | HRH3 (0.47) | PDE10AHRH3HTR3AHRH4HTR1A | |
| SCHEMBL239117 | 0.77 | HRH3 (0.52) | PDE10AHRH3HTR3AHRH4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | PDE10A 1799/4885HRH3 50/4885HTR3A 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.